MK 677 vs MK 777: What Research Shows About Ibutamoren and Its Lookalike
MK 677 vs MK 777 is a comparison with a lopsided evidence base. MK-677, also called ibutamoren, has human trials going back to the 1990s. MK-777 has none that we could find. It appears in vendor listings and in a handful of posts, and it has no peer-reviewed paper behind it.
This article covers what the MK-677 studies measured, what is claimed for MK-777, and where that conversation outruns the data. It is written for laboratory research context only. Neither compound is FDA approved, and nothing here is advice for human use.
MK 677 vs MK 777 at a Glance
- MK-677 is an oral compound that activates the ghrelin receptor. It raises growth hormone and IGF-1 in human trials.
- MK-677 is on the WADA prohibited list for competitive sport.
- MK-777 is a newer analogue with limited public data and no published human trials.
- Claims that MK-777 causes less water retention or works through calcium signaling are unverified.
- Both are research-use compounds. Neither is approved for any medical condition.
What Is MK-677 (Ibutamoren)? The Ghrelin Receptor Mechanism
MK-677 (ibutamoren) is a non-peptide growth hormone secretagogue. It mimics ghrelin, the hormone made by the stomach that signals hunger. It binds the ghrelin receptor, known as GHSR-1a, on cells in the pituitary and brain.[1] Activating that receptor prompts the pituitary to release growth hormone (GH). This growth hormone release then raises IGF-1 from the liver. The compound nudges the pituitary instead of replacing growth hormone, which is why the GH and IGF-1 axis stays under feedback control.
That mechanism sets MK-677 apart from injections of growth hormone. It works on the body’s own GH axis, so the pituitary still shapes the pulses. It also differs from GHRH analogs like those in our tesamorelin benefits guide, which act on a different receptor.
What Human Studies Found for MK-677
The human data are real, and they are mixed. Clinical results come from older adults, obese adults and young volunteers, so they do not transfer evenly. A two-year placebo-controlled trial, the longest on record, in 65 older adults found that MK-677 raised IGF-1 into the young adult range and raised fat free mass by about 1.1 kg.[2] Body weight also rose, and the added lean mass did not change strength or function. Fasting blood sugar rose and insulin sensitivity fell over the study. The most common effects were increased appetite and mild, transient edema.
Earlier work in obese adults reported higher GH secretion and more fat free mass after two months.[3] A small study of sleep found improved sleep quality, with more deep sleep and more REM sleep, within about a week.[4]
| Outcome | What studies reported | Limit |
|---|---|---|
| Growth hormone and IGF-1 | Raised in older and obese adults | Baseline levels vary by age |
| Fat free mass | Higher by about 1 kg over two years | No gain in strength or function |
| Fat loss | Not shown | Body weight rose |
| Sleep quality | Deeper sleep and more REM in a small study | Short and small |
| Blood sugar | Fasting glucose rose | Needs monitoring in any model |
| Side effects | Appetite, water retention, edema, fatigue, bloating | Reported across studies |
Higher appetite is linked to the weight gain seen in the trials, and the same mechanism is linked to the glucose changes. Claims about fat loss or healthy aging go further than the trials. The two-year study was aimed at the GH and IGF-1 axis, and it did not show less fat. Recovery and strength benefits are also unproven.
What Is Claimed for MK-777?
MK-777 shows up on vendor pages as an acetylated relative of MK-677. Those pages list a chemical formula and a higher molecular weight than MK-677. We could not confirm either against a peer-reviewed source, a PubMed record, a registered trial or a standard chemical database.
The claims you will see are:
- It also activates the ghrelin receptor to release growth hormone.
- It uses calcium-dependent signaling.
- It causes less water retention.
- It has a better side effect profile than MK-677.
Each of those is a claim, not a result. Both compounds are called growth hormone secretagogues, and that label is the only link the evidence supports. No published work presents MK-777 data on safety, GH release or water retention.
How Researchers Read the Evidence
There are three ways to test any MK-677 claim. Three questions help when you read one. First, which people were studied, and for how long? Trials ran from a few weeks to two years, and the groups differed in age and weight. Second, what was measured? Body composition, sleep and glucose each have different results, so one headline cannot cover them all. Third, how were the results presented? A rise in fat free mass sounds good until the same table shows no gain in strength.
Goals matter too. A lab studying receptor preference needs different controls than a lab studying body composition in an animal model. Adherence to a written protocol, stable stock solutions and a matched vehicle control all shape what a result means. Studies on healthy aging add another layer, since baseline GH falls with age and a rise from a low baseline is not the same as a rise from a high one. Anyone who finds a claim without a trial site, a group size and a time frame should treat it as marketing. Results without those details cannot be checked.
How the Two Compounds Compare
| Feature | MK-677 (ibutamoren) | MK-777 |
|---|---|---|
| Receptor | Ghrelin receptor (GHSR-1a) | Reported to be the same, unverified |
| Human trials | Yes, including a two-year study | None published |
| Published safety data | Yes | None found |
| Water retention | Reported in trials | Claimed lower, unverified |
| WADA status | Prohibited | Not listed by name, but falls under similar classes |
| FDA status | Not approved | Not approved |
The difference comes down to proof. MK-677 has a record that researchers can read and argue with. MK-777 has a story. A compound with no data cannot be called better, safer or cleaner.
Safety Notes and Side Effect Profile
The side effect profile of MK-677 is known from trials: more appetite, water retention, fatigue and bloating, plus higher fasting glucose. Researchers who work with it in models need to monitor blood sugar and fluid balance, and they should confirm purity with the lot COA first. A batch report is non-negotiable for any compound where the chemistry is already in question. For MK-777, no side effect profile exists to quote.
Research Use and Sourcing
MK-677 is sold here for research use only. It is not for human use, and a health history or personal goal does not change that. See MK-677 25mg capsules and the matching report in the COA library. Our lab testing page lists the panel: HPLC purity and identity, endotoxins, heavy metals and sterility, run by an ISO/IEC 17025 third-party laboratory. Read the research purposes only policy before you order, and see how to store peptides for handling. The peptide FAQ has more answers.
Research MK-677
MK 677 vs MK 777 FAQ
Is MK-777 the same as MK-677?
No. MK-777 is a separate listing that reportedly derives from MK-677. No published study confirms its structure or activity.
Does MK-677 raise IGF-1?
Yes. Human trials reported higher GH and IGF-1 levels.
Is MK-677 FDA approved?
No. It is not approved for any condition, and it is prohibited by WADA.
Does MK-777 cause less water retention?
That is a vendor claim. No data support it.
Does MK-677 improve sleep?
One small, short study reported better sleep quality. It has not been replicated in large trials.
References
- Kojima M et al. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature. 1999;402(6762):656-660. PubMed
- Nass R et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PubMed
- Svensson J et al. “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.” J Clin Endocrinol Metab. 1998;83(2):362-369. PubMed
- Copinschi G et al. “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.” Neuroendocrinology. 1997;66(4):278-286. PubMed
- World Anti-Doping Agency. “Prohibited List.” WADA
Research use only
COA-pep products are sold for laboratory research only. They are not drugs, foods, cosmetics or dietary supplements, and they are not for human or veterinary use. Nothing in this article describes effects in people or offers guidance for use in people.
English
French
Spanish
